146 related articles for article (PubMed ID: 38488034)
21. Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Zhang Z; Gao S; Xu Y; Zhao C
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200805
[TBL] [Abstract][Full Text] [Related]
22. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
24. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
25. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
26. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
27. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
28. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
29. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
Liau SS; Ashley SW; Whang EE
J Gastrointest Surg; 2006 Nov; 10(9):1254-62; discussion 1263. PubMed ID: 17114012
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
31. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
32. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
[TBL] [Abstract][Full Text] [Related]
33. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
34. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
35. Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Tian Y; Han W; Fu L; Lv K; Zhou X
Environ Toxicol; 2023 Aug; 38(8):1835-1845. PubMed ID: 37186415
[TBL] [Abstract][Full Text] [Related]
36. Downregulated expression of IL‑28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma.
Liu L; Qi Y; Huang D; Xu Y; Li M; Hong Z; Gu Y; Jia B; Luo X; Zhang S; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195850
[TBL] [Abstract][Full Text] [Related]
37. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
38. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
[TBL] [Abstract][Full Text] [Related]
39. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
40. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
